MGX · Metagenomi, Inc. Common Stock

Summary

Metagenomi Therapeutics, Inc. reported full year 2025 financial results including $25.2 million collaboration revenue, $94.4 million R&D expenses, and $87.9 million net loss, with $160.8 million in cash providing runway through 4Q 2027. The company completed pre-IND meeting for MGX-001 hemophilia A program and remains on track for IND submission in 4Q 2026.

Key takeaways

• Cash, cash equivalents, and marketable securities of $160.8 million as of December 31, 2025, with runway through 4Q 2027
• R&D expenses $94.4 million for 2025 vs $109.2 million for 2024
• G&A expenses $26.8 million for 2025 vs $32.0 million for 2024
• Net loss $87.9 million for 2025
• Completed pre-IND meeting for MGX-001 and on track for IND in 4Q 2026
• Corporate name change to Metagenomi Therapeutics, Inc.